In The Hot Seat: Bristol Defends IO Position Amid Sliding Stock And Forecasts

18 Apr 2018

• By Emily Hayes

Bristol's stock price dipped after the AACR meeting, where pivotal lung cancer data for Opdivo/Yervoy disappointed relative to Merck's Keytruda/chemo combo, but Bristol still has many immuno-oncology irons in the fire in other indications and expressed confidence in its strategy.

Faced with a backlash over the showing of its Opdivo/Yervoy combo in first-line lung cancer – the big prize in immuno-oncology – at the American Association for Cancer Research (AACR) meeting, Bristol-Myers Squibb Co. is defending its long-term strategy, which is grounded in a chemo-sparing, biomarker-driven, multi-mechanism approach across tumor types.

The company was put in the defensive position on April 16 after the AACR meeting and the New England Journal...